Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Orchestra BioMed to $15 from $20 and keeps an Overweight rating on the shares. The firm notes Orchestra Biomed reported Q3 results along with an update on the business. While Orchestra remains early, the combination of clinical need and unique operating agreements with larger companies makes this an early stage company to own.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on OBIO:
- Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update
- Orchestra BioMed to Present at Upcoming Investor Conferences
- Orchestra BioMed files to sell 22.22M shares of common stock for holders
- Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients